TelconRF Pharmaceutical: Capital Reduction to Cover Deficits
- Capital reduction to cover deficits; proceeds by ordinary resolution, skipping creditors' objection procedure
- Fractional shares from consolidation to be paid in cash at closing price on first listing day of new shares
- Reduction details may change based on the outcome of a third-party allocation paid-in capital increase scheduled for April 17, 2026
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: Current Report (Capital Reduction Decision)
- Company: Telcon RF Pharmaceutical (200230)
- Submission: Telcon RF Pharmaceutical. Inc.
- Receipt: 04-08-2026
- Amended (Refer to related filing)